Boston Scientific Corporation (BSX) Stock Price, News, Analysis

Technical Score (1D)

SELL

News Sentiment

BEARISH

Citigroup’s 1.2‑hour‑old downgrade of Boston Scientific to Neutral, coupled with a $7 cut in the price target, signals a reassessment of the company’s earnings outlook amid mounting competitive pressure in the medical‑device sector. The rating shift is likely to dampen short‑term investor enthusiasm and could prompt a pullback in the stock over the next few trading days. The 8.5‑hour recall of the LUX‑Dx cardiac monitor for delayed atrial‑fibrillation alerts adds regulatory risk; the recall’s breadth and any associated liability costs could further weigh on earnings and erode clinician confidence in a core product line. The recall also raises the possibility of increased FDA scrutiny, which may delay future product approvals or require costly redesigns. Meanwhile, the 19.9‑hour report that two U.S. congressmen purchased BSX shares after a cyberattack‑induced production pause suggests that political investors see a rebound in operations, as distribution centers are now back to or above normal levels. This political buying may counterbalance some of the negative sentiment, but the market will still be watching for any lingering supply chain disruptions or additional cyber‑security incidents. In the next 1–10 trading days, traders should monitor Citigroup’s updated earnings guidance for any further downgrades, the progress of the LUX‑Dx recall resolution, and any FDA statements on the device’s safety. A sudden change in the recall scope or a new regulatory directive could quickly alter the stock’s trajectory, while a steady recovery in production and a positive earnings report could help stabilize the share price.

BSX|Analyst Targets

LOW TARGET

$44 +1.5%

2 analysts

MEAN TARGET

$62 +42.5%

13 analysts

HIGH TARGET

$94 +116.9%

25 analysts

PRICE RANGE

$44.00 - $94.00

SB / B / H / S / SS

11/19/8/1/1

DAILYIQ EST.

$66.63 (+53.7%)

BSX|Company Info

Sector

Healthcare

Industry

Medical Devices

Exchange

NYQ

Country

United States

Website

bostonscientific.com

Symbol

BSX

Description

Boston Scientific Corporation is a global medical device manufacturer specializing in interventional medical specialties. The company's core business involves developing, manufacturing, and marketing a diverse portfolio of devices used in the MedSurg and Cardiovascular segments. These offerings span a wide range of applications, including gastrointestinal, urological, and neurological treatments, as well as devices for managing chronic pain. Boston Scientific also provides critical technologies for diagnosing and treating cardiovascular diseases, including coronary artery disease and aortic valve conditions, along with devices for heart rhythm management and peripheral arterial disease. Incorporated in 1979, the company is headquartered in Marlborough, Massachusetts.

BSX|Insider Trading

Bought (1Y)

206,362 shares

$10.0M

Sold (1Y)

1,577 shares

$71K

O'Connor Padraig AndrewEVP, Global Operations

Option Exercise1,171 shares2026-09-02

O'Connor Padraig AndrewEVP, Global Operations

Tax Withholding567 shares2026-09-02

O'Connor Padraig AndrewEVP, Global Operations

Option Exercise1,171 shares2026-09-02

Morano Susan E-

Buy2,040 shares2026-08-25

Woodworth EmilySVP, Global Controller and CAO

I2,930 shares2026-08-11

BSX|Fundamentals

Strong bullish

Verdict: Bullish

✓Revenue growing year over year

✓Positive net margin

✓Positive operating cash flow

Gross Margin

69.0%

Net Margin

14.4%

Revenue CAGR

5.0%

Current Ratio

1.62x

Debt / Equity

0.47x

Return on Equity

11.9%

BSX|Earnings Snapshot

Earnings Summary

Boston Scientific Corporation is a global medical device manufacturer focused on interventional medical specialties, offering a broad portfolio across gastrointestinal, urological, neurological, chronic pain, and cardiovascular segments, including coronary and aortic valve technologies. The company operates within the highly regulated healthcare sector, where product innovation and regulatory compliance drive growth. Recent quarterly performance shows a steady revenue trajectory, with Q1‑2025 revenue at $4.663B and Q2‑2025 at $5.061B, a 8.6% year‑over‑year increase, while Q3‑2025 revenue held flat at $5.065B, indicating a slight deceleration. EPS has remained robust, with Q1‑2025 EPS of $0.75 beating estimates of $0.6725, and Q2‑2025 EPS of $0.75 versus an estimate of $0.7252, demonstrating consistent earnings strength. The company has beaten analyst estimates in three of the last four quarters, maintaining a positive earnings trend despite revenue volatility. Historically, Boston Scientific has delivered double‑digit YoY revenue growth over the past three years, with EPS growth outpacing revenue in several periods. The company has frequently surpassed earnings expectations, even when revenue growth slowed, reflecting effective cost management and pricing power. Notably, the Q4‑2025 revenue fell slightly below the $5.333B estimate, yet EPS still beat at $0.80 versus $0.7873, underscoring resilience. Recent news highlights a Citigroup downgrade to Neutral and a $7 price‑target cut, driven by competitive pressure and a recall of the LUX‑Dx cardiac monitor, which introduces regulatory risk and potential liability costs. The recall could impact future earnings and clinician confidence, while the downgrade may dampen short‑term investor enthusiasm. Investors should watch for the next earnings guidance release to assess the impact of the LUX‑Dx recall resolution and any updates on regulatory scrutiny, as well as the company’s ability to sustain EPS growth amid revenue headwinds. Key will be how the recall costs are managed and whether the company can maintain its cost discipline to preserve margins in the coming quarter.

Read full report

EPS

EstBeatMiss

Qtr	Est	Actual	+/−
Q3'26	$0.78	-	-
Q2'26	$0.83	$0.86	+3.9%
Q1'26	$0.79	$0.80	+1.6%
Q4'25	$0.79	$0.80	+1.6%
Q3'25	$0.71	$0.75	+5.1%
Q2'25	$0.73	$0.75	+3.4%

Revenue

EstBeatMiss

Qtr	Est	Actual	+/−
Q3'26	$5.3B	-	-
Q2'26	$5.4B	$5.4B	+0.5%
Q1'26	$5.2B	$5.2B	+0.6%
Q4'25	$5.3B	$5.3B	-0.9%
Q3'25	-	$5.1B	-
Q2'25	-	$5.1B	-

Full Earnings BreakdownEstimates, actuals, guidance, and historical context

→

BSX|Monthly Returns

Market Data

BSX Stock Snapshot

SELL27/100

$43.47+$0.07 (0.2%)

Market cap: 62.81B
P/E ratio: 17.1
Day range: $43.05 – $43.90
News sentiment: 31/100 · Bearish
Analyst target: $61.76 (+42.1%)
Consensus: Buy · 40 analysts

52-week range+4.8% off low · -58.9% from high

$41.49$105.65

Price $43.47 DailyIQ Est. $66.63

BSX is on the weaker side of its setup, with little confirmation for a reversal yet. The stock is liquid enough that positioning changes get absorbed without distorting the trend.

Reverse DCF

What growth is priced into BSX?

CHEAP

At today's price, Boston Scientific Corporation needs to grow free cash flow about 3.8% a year for the next 10 years to justify its valuation at a 7.85% cost of capital. Over its actual history it has compounded free cash flow at 10.7% a year, so the market is asking for 6.9 percentage points below its own delivered rate. On that basis BSX looks priced below what its own growth record supports.

Implied FCF growth: 3.8%
Historical FCF CAGR: 10.7%
Growth gap: -6.9 pts
Verdict: CHEAP
Discount rate (WACC): 7.85%
Beta: 0.77

Behaviour On Record

What BSX's own history says about today's numbers

Realized volatility (21d): 43.8% 94th pct
Below its peak: -60.2%
vs 200-day average: -33.0%
Up days (1y): 46%

Boston Scientific Corporation is currently running 43.8% annualised volatility over the last 21 sessions. Measured against BSX's own 13 years of daily returns rather than a market-wide average, that is the 94th percentile — an extreme by its own standards, against a typical reading of 23.4%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

BSX is trading -60.2% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -17.7%, and the deepest was -42.5% in 2020. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits -33.0% from its 200-day moving average. Against every other day in its history, that gap ranks at the 3rd percentile — a narrower gap than it typically runs. Over the past year BSX closed higher on 46% of sessions, and it is currently 4 sessions into a falling streak.

On September specifically: over 13 years of records, BSX finished the month higher 4 of 13 times, with a median return of -2.4% and an average of -2.4%. Its strongest month historically has been January at +5.5% on average, its weakest September at -2.4%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: BSX has opened more than 2% away from the prior close in 124 of 3,267 sessions (3.8% of the time), with the largest gaps running +9.8% and -9.7%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, BSX moved an average of 1.4% in the session after earnings, closing higher 2 of those 3 times, with a median move of +1.5% and a largest of +2.1%.

All figures computed from 3,268 daily closes between 2013-09-20 and 2026-09-18, split-adjusted, recomputed daily. Percentiles are against BSX's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of BSX's sector?

Boston Scientific Corporation sits in the Health Care sector, currently ranked 4th of 11 GICS sectors by relative-strength rotation score (improving). Within its narrower Medical Devices industry group, BSX ranks 12th of 15 tracked industries, improving.

Sector rank: #4 of 11
Sector state: Improving
Sector rotation score: 100
Industry rank: #12 of 15

Options Market

What is the options market pricing for BSX?

CallsPuts

For Boston Scientific Corporation's nearest expiry (2026-09-25, 5 days out), open interest is put-heavy, a defensive/bearish tilt (put/call ratio of 1.32), with at-the-money implied volatility around 46.9%. The options market is pricing roughly a ±5.6% move by that expiry — a range of about $41.38–$46.29.

Put/call ratio (2026-09-25): 1.32
ATM implied volatility: 46.9%
Total open interest: 8,737
Expected move by 2026-09-25: ±5.6% ($41.38–$46.29)

Analyst Rating Changes

Are analysts turning bullish or bearish on BSX?

Citigroup most recently downgraded Boston Scientific Corporation to Neutral on Sep 17, 2026 with a price target of $50 (from $57). Over the last 90 days, coverage has run 0 upgrades against 2 downgrades, a net bearish lean.

Latest action: Citigroup — Neutral
90-day upgrades: 0
90-day downgrades: 2
Net rating momentum: -2

Date	Firm	Action	Rating	Price target
Sep 17, 2026	Citigroup	Downgrade	Buy → Neutral	$57 → $50
Sep 9, 2026	BTIG	Maintained	Buy	$60 → $56
Aug 25, 2026	TD Cowen	Reiterated	Buy	$56
Jul 31, 2026	Argus Research	Downgrade	Buy → Hold	-
Jul 30, 2026	UBS	Maintained	Buy	$74 → $67
Jul 30, 2026	Citigroup	Maintained	Buy	$70 → $61
Jul 30, 2026	RBC Capital	Maintained	Outperform	$85 → $70
Jul 30, 2026	TD Cowen	Maintained	Buy	$61 → $56
Jul 30, 2026	Canaccord Genuity	Maintained	Buy	$70 → $66
Jul 30, 2026	Truist Securities	Maintained	Buy	$62 → $57
Jul 30, 2026	Evercore ISI Group	Maintained	Outperform	$65 → $55
Jul 30, 2026	Wells Fargo	Maintained	Equal-Weight	$55 → $50

BSX Competitive Positioning

Boston Scientific Corporation (BSX) is tracked alongside these names in Medical Devices on DailyIQ — ranked by market cap, with today's move alongside.

BSXyou're hereBoston Scientific Corporation$62.8B+0.16%
MDTMedtronic plc$117.8B-0.02%
SYKStryker Corporation$105.5B+0.45%
DXCMDexCom, Inc.$33.7B+0.28%
STESTERIS plc$20.0B-0.06%
ZBHZimmer Biomet Holdings, Inc.$18.2B+1.15%

Held by These ETFs

BSX is a top holding in these ETFs tracked on DailyIQ — bar length shows portfolio weight.

News Sentiment Analysis

Sentiment gathered from recent headlines

31/100

Strong NegativeNeutralStrong Positive

BEARISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles

What did this article say?

Citigroup lowered Boston Scientific (BSX) to neutral from buy and trimmed its target price to $50 from $57, prompting a 1% decline in shares. The downgrade reflects concerns over the company’s valuation and future earnings growth. Market reaction was muted, with volume slightly below the 20.4‑million daily average. The move signals a modest negative outlook for BSX, potentially influencing investor sentiment and short‑term trading.

What did this article say?

Boston Scientific’s stock has fallen 55% over the past year, prompting investors to question whether the current price reflects the company’s cash‑flow generation capability. The article highlights the firm’s reliance on converting its medical‑device portfolio into recurring cash and notes that the 17.3x P/E ratio may signal undervaluation relative to peers. Analysts suggest comparing the discounted cash‑flow estimate to the market price to assess whether sentiment has overshot fundamentals. The piece also encourages investors to review a broader set of high‑quality undervalued stocks for context.

What did this article say?

Citi has downgraded Boston Scientific to Neutral from Buy, cutting its price target to $50 from $57. The downgrade reflects an uncertain recovery path, citing a more mature and competitive U.S. market for pulsed field ablation, stagnating left atrial appendage closure, hiccups in urology, and a cybersecurity attack. Multiple revisions this year have eroded confidence, and key growth drivers remain under pressure. Management guidance indicates a decline in the closure market into the second half of 2027, with potential impacts on the Watchman device uptake.

What did this article say?

Citigroup has downgraded Boston Scientific (BSX) from a Buy to a Neutral rating and reduced its price target from $57 to $50. The move reflects a reassessment of the company’s growth prospects and competitive positioning. The downgrade signals a shift in analyst sentiment and may influence investor expectations for the upcoming earnings period. Traders should monitor how the market reacts to the new target and any subsequent commentary from other research houses.

What did this article say?

Citigroup’s analyst Joanne Wuensch has downgraded Boston Scientific (BSX) from a Buy to a Neutral rating, citing concerns over earnings growth and competitive pressure. The brokerage reduced its price target from $57 to $50, signaling a more cautious outlook on the company’s near‑term profitability. This downgrade reflects a reassessment of BSX’s valuation relative to peers and may influence investor sentiment ahead of the upcoming earnings release.

What did this article say?

Citigroup has downgraded Boston Scientific (BSX) from a Buy to a Neutral rating and reduced its price target from $57 to $50. The move reflects concerns over the company’s earnings outlook and competitive pressures in the medical device sector. The downgrade signals a reassessment of BSX’s growth prospects and may influence investor sentiment and trading activity.

What did this article say?

Boston Scientific has launched a voluntary global recall of its LUX‑Dx Insertable Cardiac Monitor System and associated software due to delayed atrial fibrillation burden alerts. The recall covers multiple hardware versions and software builds that may postpone detection of arrhythmias, raising regulatory scrutiny from the FDA. The issue directly impacts a core product line used in patient monitoring and could erode trust with clinicians and payers. Investors should monitor the recall’s scope, potential liability costs, and any impact on sales of related devices.

What did this article say?

Boston Scientific (BSX) attracted purchases from two U.S. congressmen, signaling renewed confidence from political investors. The trades followed a cyberattack that had temporarily halted manufacturing and forced a downgrade of the company’s guidance. By early September, BSX reported that distribution centers were operating at or above normal levels and most plants had resumed production. The positive investor activity suggests the market may have overreacted to the cyber incident, and the company’s recovery trajectory could support a modest upside.

What did this article say?

Boston Scientific (BSX) has been added to Zacks’ Strong Sell list, reflecting a modest 1.8% downward revision to its current‑year earnings estimate. The downgrade signals a slight negative outlook for the company, though the impact is limited compared to larger catalysts. Investors should note that the rating change is based on consensus estimates rather than a fundamental shift in the business model. The move may influence short‑term trading activity but is unlikely to trigger a major market reaction. Monitoring subsequent earnings releases and analyst updates will clarify whether the downgrade is temporary or indicative of deeper issues.

What did this article say?

Boston Scientific’s shares have dropped 57% year‑to‑date, trading at a 3.2× trailing sales multiple near a decade‑low. The decline reflects stalled growth in its two fastest‑growing franchises, WATCHMAN and another, with management projecting mid‑ to high‑single‑digit sales declines in 2026. Despite a three‑year widening of operating margin, the valuation suggests market sentiment remains depressed and any further guidance cuts could lower the price floor.

Technical Analysis

Real-time indicators across multiple timeframes

SELL

Technical indicators reflect the latest computed signal mix for this timeframe.

Unlock full technicals

Create a free account to access more indicators and deeper timeframe data.

Institutional & Hedge Fund Ownership

25 tracked managers · $35.50B combined position · 12 adding, 11 trimming, 2 unchanged (latest 13F filings)

Manager	Trend	Shares Held	% of Co.	Position Value	Filed
Vanguard Group Inc	▲ Buy	139,685,997	9.67%	$13.32B	2026-01-29
BlackRock, Inc.	▼ Sell	129,680,916	8.98%	$5.53B	2026-08-07
FMR LLC (Fidelity)	▼ Sell	45,702,845	3.16%	$1.95B	2026-08-13
Geode Capital Management, LLC	▲ Buy	33,440,102	2.31%	$1.42B	2026-08-12
JPMorgan Chase & Co	▼ Sell	28,133,038	1.95%	$1.22B	2026-08-12
D. E. Shaw & Co., Inc.	▲ Buy	27,267,209	1.89%	$1.16B	2026-08-14
Janus Henderson Group plc	• Hold	16,497,366	1.14%	$1.04B	2026-05-18
Norges Bank	▼ Sell	21,170,029	1.47%	$903.54M	2026-08-12
Two Sigma Investments, LP	▲ Buy	19,420,323	1.34%	$828.86M	2026-08-14
Goldman Sachs Group Inc	▼ Sell	19,207,742	1.33%	$819.79M	2026-08-14
Morgan Stanley	▼ Sell	18,947,147	1.31%	$808.66M	2026-08-13
Capital World Investors	▲ Buy	16,812,257	1.16%	$717.60M	2026-08-12
Wellington Management Group LLP	▼ Sell	15,301,828	1.06%	$653.08M	2026-08-14
Capital Research Global Investors	▲ Buy	14,180,571	0.98%	$605.26M	2026-08-12
Invesco Ltd.	▲ Buy	13,800,748	0.96%	$589.02M	2026-08-14
Bank of America Corp	▼ Sell	13,027,783	0.90%	$556.03M	2026-08-14
Northern Trust Corp	▼ Sell	12,964,638	0.90%	$553.33M	2026-08-13
Egerton Capital (UK) LLP	▲ Buy	5,385,084	0.37%	$513.47M	2026-02-11
Farallon Capital Management LLC	▲ Buy	10,521,184	0.73%	$449.04M	2026-08-14
Citadel Advisors LLC	• Hold	10,155,348	0.70%	$433.43M	2026-09-02
AQR Capital Management LLC	▲ Buy	9,681,750	0.67%	$413.22M	2026-08-14
Susquehanna International Group, LLP	▼ Sell	6,554,450	0.45%	$279.74M	2026-08-14
Maverick Capital Ltd	▲ Buy	5,937,553	0.41%	$253.41M	2026-08-14
Viking Global Investors LP	▼ Sell	2,509,808	0.17%	$239.31M	2026-02-17
Millennium Management LLC	▲ Buy	5,938,867	0.41%	$232.13M	2026-08-14

Q2 2026 flow:35.18M sh bought ($1.50B)56.57M sh sold ($2.42B)net -21.39M sh (−$920.12M)

Congressional Trading Activity

25 disclosed trades · ~$249.0K est. traded value · 10 buys, 15 sells

Member	Chamber	State	Type	Amount	Traded	Filed
Gilbert Cisneros	House	CA31	▲ Buy	$1K - $15K	2026-08-18	2026-09-10
Gilbert Cisneros	House	CA31	▲ Buy	$1K - $15K	2026-06-05	2026-07-02
Gilbert Cisneros	House	CA31	▼ Sell	$1K - $15K	2026-06-05	2026-07-02
Gilbert Cisneros	House	CA31	▲ Buy	$1K - $15K	2026-05-29	2026-06-08
Gilbert Cisneros	House	CA31	▲ Buy	$1K - $15K	2026-05-19	2026-06-08
Gilbert Cisneros	House	CA31	▲ Buy	$1K - $15K	2026-05-11	2026-06-08
Gilbert Cisneros	House	CA31	▲ Buy	$1K - $15K	2026-02-10	2026-03-09
Gilbert Cisneros	House	CA31	▲ Buy	$1K - $15K	2026-01-30	2026-02-13
Gilbert Cisneros	House	CA31	▼ Sell	$1K - $15K	2025-12-24	2026-01-12
Gilbert Cisneros	House	CA31	▲ Buy	$1K - $15K	2025-11-18	2025-12-15
Lisa McClain	House	MI09	▼ Sell	$1K - $15K	2025-10-31	2025-11-21
Lisa McClain	House	MI09	▼ Sell	$1K - $15K	2025-10-30	2025-11-21
Lisa McClain	House	MI09	▲ Buy	$1K - $15K	2025-10-30	2025-11-21
Kevin Hern	House	OK01	▼ Sell	$15K - $50K	2025-10-28	2025-11-16
Gilbert Cisneros	House	CA31	▲ Buy	$1K - $15K	2025-10-17	2025-11-18
Valerie Hoyle	House	OR04	▼ Sell	$1K - $15K	2025-09-23	2025-10-10
Lisa McClain	House	MI09	▼ Sell	$1K - $15K	2025-08-04	2025-09-12
Gilbert Cisneros	House	CA31	▼ Sell	$1K - $15K	2025-07-31	2025-08-14
Gilbert Cisneros	House	CA31	▼ Sell	$1K - $15K	2025-06-26	2025-07-10
Gilbert Cisneros	House	CA31	▼ Sell	$1K - $15K	2025-06-11	2025-07-10
Gilbert Cisneros	House	CA31	▼ Sell	$1K - $15K	2025-05-13	2025-06-06
Jefferson Shreve	House	IN06	▼ Sell	$15K - $50K	2025-05-12	2025-06-22
Gilbert Cisneros	House	CA31	▼ Sell	$1K - $15K	2025-04-28	2025-05-06
Bruce Westerman	House	AR04	▼ Sell	$1K - $15K	2025-04-21	2025-05-12
Gilbert Cisneros	House	CA31	▼ Sell	$1K - $15K	2025-03-17	2025-04-07

BSX·Boston Scientific Corporation

EPS

Revenue

BSX Stock Snapshot

What growth is priced into BSX?

What BSX's own history says about today's numbers

Is money rotating into or out of BSX's sector?

What is the options market pricing for BSX?

Are analysts turning bullish or bearish on BSX?

BSX Competitive Positioning

Held by These ETFs

News Sentiment Analysis

Recent News Coverage

Technical Analysis

Real-time indicators across multiple timeframes

News Sentiment Analysis

Recent News Coverage

Technical Analysis

Real-time indicators across multiple timeframes

Market Status

Recently Viewed

Portfolio

Email Alerts

Portfolio News

Economic Events

Earnings Events

Economic News

BSX·Boston Scientific Corporation

EPS

Revenue

BSX Stock Snapshot

What growth is priced into BSX?

What BSX's own history says about today's numbers

Is money rotating into or out of BSX's sector?

What is the options market pricing for BSX?

Are analysts turning bullish or bearish on BSX?

BSX Competitive Positioning

Held by These ETFs

News Sentiment Analysis

Recent News Coverage

Technical Analysis

Real-time indicators across multiple timeframes

Discover More

News Sentiment Analysis

Recent News Coverage

Technical Analysis

Real-time indicators across multiple timeframes

Discover More

Market Status

Recently Viewed

Portfolio

Email Alerts

Portfolio News

Economic Events

Earnings Events

Economic News